The hallmark of infection by human herpesviruses, life-long persistence in the host, is unaffected by current antiviral therapies effective against replication of virus. In vitro studies indicated that low concentrations of the ribonucleotide reductase inhibitor, hydroxyurea, completely eliminated Epstein-Barr virus (EBV) episomes from latently infected Burkitt's lymphoma (BL) cell subsets, providing the first example of chemotherapeutic eradication of a latent herpesvirus from any cell population. Unlike parental EBV-positive BL cells, virus-free cell progeny from one treated cell line no longer exhibited the malignant phenotype in tumorigenicity assays. Hydroxyurea-treated primary B lymphocytes immortalized by EBV ceased to proliferate as episomes were lost. The altered growth phenotype of both BL cells and immortalized primary B cells suggests that latent EBV is an appropriate and accessible therapeutic target for treatment of some EBV-induced lymphoproliferations.
The Epstein-Barr virus (EBV) is a transforming human
EBV-immortalized as well as malignantly transformed lymphoid cells that reflect the heterogeneity of EBV lymphogamma-herpesvirus that in its latent state is associated with Burkitt's lymphoma (BL), nasopharyngeal carcinoma, Hodgproliferative diseases. The intent was to determine if the elimination of EBV episomes might offer a clinical strategy for kin's lymphoma, and lymphoproliferative disorders of immunosuppressed patients. Little consideration has been given to antiviral intervention in EBV-associated lymphoproliferations. therapeutic strategies that target EBV in virus-associated malignancies, first, because latent herpesvirus infection is intractable Materials and Methods to available antiviral chemotherapy [1, 2] , and, second, because of the uncertainty that EBV contributes to the long-term mainCell lines and hydroxyurea treatment. The cell lines studied tenance of the malignant cell phenotype. In tumors such as BL, were four EBV-positive BL tumor-derived lines (Akata [13] , latency-associated viral proteins critical to successful growth Mutu [14] , Raji [15] , Namalwa [16] ) and four EBV-immortalized transformation of primary B lymphocytes are down-regulated lymphoblastoid cell lines (IB4 [17] ; TW236, established by immor- [3, 4] . talization of umbilical cord blood lymphocytes with a throat-washIn the latent state, the EBV genome is maintained as circular ing isolate; AB, obtained by transformation of adult peripheral blood lymphocytes with laboratory strain B95-8; and RR, derived extrachromosomal DNA with multiple (but varying) copies per from spontaneously transforming peripheral blood lymphocytes of cell [5 -8] that replicate in synchrony with cellular DNA during a bone marrow transplant patient with lymphoproliferative disthe cell cycle [9] . Because the ribonucleotide reductase inhibiease). Because of spontaneous EBV DNA loss reported in longtor hydroxyurea has been shown to accelerate the loss of extraterm (ú6 months) cultures of the Akata BL cells [18] , newly chromosomally amplified myc and drug-resistance genes from derived EBV-positive clones established by cell sorting were used human tumor cell lines [10 -12] , we used the drug to treat in these experiments to ensure a uniform population of EBVinfected cells. Cell cultures were seeded at 5 1 10 5 cells/mL and continuously exposed to hydroxyurea (Sigma, St. Louis) at 50 mM. Cells were counted twice weekly, and their viability was tested by with BamHI, and electrophoresed in 0.8% agarose gels. After taining 50 mM hydroxyurea, a concentration far below achievSouthern transfer, blots were hybridized to a 32 P-labeled probe able serum levels of the drug (500 -2500 mM) observed clini-(random primed DNA labeling kit; Boehringer Mannheim, Indiacally during treatment of neoplasia [25] . At the 50-mM level, contain episomes but has two copies of EBV DNA integrated DNA, IR1, as described previously [22] . Then, growth kinetics of into host chromosomes [16, 26, 27] , predictably did not exhibit EBV-positive and EBV-negative clones in the presence of 50 mM a reduction in viral DNA with treatment (data not shown).
hydroxyurea were determined over an 8-week period in culture.
Viral DNA content of BL cells at the single-cell level. At
Determination of cell growth phenotype. Growth characterisan individual cell level, there was complete eradication of EBV tics of EBV-positive and EBV-negative clones, seeded at 1 1 10 5 DNA from treated cell subsets in two BL lines examined, Akata cells/mL, were determined in RPMI 1640 medium containing 0.1% FBS over 1 week in culture. Anchorage-independent growth in and Mutu. When analyzed for EBV DNA by FISH, untreated soft agar was assessed in 0.33% agarose (SeaPlaque; FMC Bioproducts, Rockland, ME) as described [18] . Tumorigenicity of treated and untreated cell clones was assayed in 6-to 8-week-old SCID mice (St. Jude Children's Research Hospital Animal Resources Center). Cells (2 1 10 7 ) from EBV-positive and EBV-negative clones suspended in 200 mL of PBS were injected subcutaneously into the left and right flank, respectively. Four mice were injected per EBV-negative clone tested. Mice were euthanized if tumors exceeded 2 cm or if mice appeared ill. All resultant tumors were screened for EBV by DNA hybridization analysis.
Results

Reduction of viral DNA from treated BL cell populations.
The BL-derived cell line, Akata, has been shown to lose EBV DNA spontaneously from cell subpopulations during long-term figure 2A ). By contrast, almost half of the hyGrowth characteristics of hydroxyurea-treated BL cells. BL cells share growth properties intrinsic to most cancer cells: droxyurea-treated Akata cells contained no signal whatsoever (figure 2B), and those that retained episomes had an overall reduced serum requirements in culture, growth in soft agar, and tumorigenicity in immunodeficient mice. Because latent lower copy number than did untreated cells ( figure 2C ). Complete episome loss was also detected in treated Mutu cell popu-EBV proteins critical to cell transformation and growth proliferation in vitro (EBNA-LP, EBNA2, EBNA3a, EBNA3c, and lations that had no discernable EBV DNA reduction on Southern analysis, but only in the occasional cell (not shown).
LMP1) are not expressed in BL cells [3, 4] , it has generally been assumed that virus, although important for tumor initiaAs corroboration of results obtained by FISH analysis, 57 (43%) of 131 cell clones derived from the hydroxyurea-treated tion, does not contribute to the long-term maintenance of the malignant cell phenotype [28] . To examine the effect of inAkata cell population by single-cell sorting were EBV-negative as determined by PCR analysis and by immunoblot detection duced episomal DNA loss on BL cell growth, four cell clones each from the two tumor cell lines cured of viral episomes of the EBV nuclear antigen 1 (EBNA1). Four (2%) of 169 cell clones established from treated Mutu BL cells were EBVwere compared in tumorigenicity assays to respective EBVpositive clones. negative versus none from untreated cell populations. Cytogenetic studies of the EBV-negative clones demonstrated the Whereas growth of EBV-positive and EBV-negative Akata clones was comparable in medium containing 10% FBS, only EBV-positive cell clones were capable of proliferation in 0.1% FBS ( figure 3A) ; the EBV-negative counterparts ceased to grow under these conditions, and cells were no longer viable beyond 7 days. Serum dependency of EBV-negative Akata clones did not simply reflect toxic effects of prior hydroxyurea exposure, since treated cell clones that retained EBV DNA grew at the same rate in 0.1% FBS-containing medium as did untreated, EBV-positive cells ( figure 3A) . In soft agar growth assays, EBV-positive Akata cells formed visible colonies within 3 weeks. By contrast, no cell clone from which EBV DNA had been eliminated produced colonies ( figure 3B) . Notably, EBVnegative Mutu BL cell clones (unlike virus-negative Akata cells) did not show impaired growth in either liquid or semisolid growth media compared with that of their EBV-positive counterparts, perhaps reflecting additional stepwise changes in cell context that occur throughout tumor progression [29, 30] .
In vivo tumorigenicity assays were done in SCID mice with virus-free cell clones derived from both treated BL lines. Four cell clones from each BL line were used, and EBV-negative cells were injected subcutaneously into 4 mice each at an inoculum of 2 1 10 7 cells. The respective EBV-positive parental BL clones were injected into the opposite flank as controls. At 6 weeks after injection, 10 of 15 surviving mice had developed large masses from EBV-positive Akata cells, with no evidence of tumor formation at the site of inoculation of EBV-negative Akata BL clones (P õ .001, Fisher's exact test, two-tailed; figure 3C ). All tumors were EBV-positive by PCR assay, confirming their derivation from injected human cells. In agreement with in vitro assays, a comparable change in growth pattern was not observed with four EBV-negative clones iso- growth of primary B cells infected with EBV is virus-depen-almost identical to those of the untreated control (figure 4A), a pattern consistent with that observed with most tumor-derived lines maintained on the low concentration of drug [10, 12] .
In contrast, the population doublings of a lymphoblastoid cell line (TW236) containing EBV DNA in an episomal configuration were markedly reduced in the presence of hydroxyurea ( figure 4B) . Moreover, the growth of a second lymphoblastoid cell line (RR), derived from spontaneously transforming peripheral blood lymphocytes of a patient with posttransplant EBV lymphoproliferative disease, could not be sustained with treatment ( figure 4C ). The impaired growth of hydroxyureatreated lymphoblastoid cell lines coincided with diminished EBV episome numbers as determined by FISH analysis. The median hybridization signal count per cell in hydroxyureatreated versus untreated TW236 cells was 6 versus 21 (P õ .001, Wilcoxon two-sample test), a result almost identical to that achieved in a third lymphoblastoid cell line (AB; not shown). Indeed, complete absence of hybridization signals over some cells in the treated populations (figure 5) is consistent with an apparent reversal of lymphocyte immortalization accompanying drug-induced EBV DNA loss.
Discussion
Tumors arise through an accumulation of genetic changes affecting the control of cell growth [37, 38] . BL was one of the first cancers for which the multistep nature of neoplasia could be defined in terms of successive biologic and molecular events: EBV-induced B cell immortalization complemented by deregulation of c-myc through the characteristic t(8; 14) translocation found in BL tumors [28] . The likely temporal sequence for these two genetic ''hits'' (and consequently the contribution from viral genes to the proliferation of cells carrying the trans- type of Akata BL cells despite the presence of the translocated c-myc gene, confirming an earlier report of BL dependence on the presence of EBV genomes [18] . The enforced loss of epident, successful eradication of viral DNA should equate with an inability to maintain cells in long-term culture. Given the somes achieved here with hydroxyurea in short-term culture establishes a direct link between virus loss and altered growth considerable variation in episomal copy number from cell to cell in any infected line [31 -33] , cell death due to early virus phenotype, which as spontaneous events in long-term culture could have been merely coincidental. Our results also imply eradication from subpopulations with the fewest episomes would manifest only as slowed cell doubling time. To assure that BL dependence on EBV may not extend through all evolutionary stages of the malignancy. For example, the contradicthat any observed change in growth phenotype reflected episomal DNA loss and not a manifestation of other potential tory impact of viral DNA eradication on growth of clones derived from Akata versus Mutu BL cells most likely reflects drug effects [34, 35] [42] . One might speculate Akata, contributes to tumorigenicity of BL is as yet unclear, but our finding adds to accumulating evidence for the oncogenic potential for this protein when expressed in the absence of other viral gene products [43, 44] . In dividing cells, EBNA1 is known to play a crucial role in EBV genome persistence and episomal DNA replication [45, 46] . In lymphoblastoid cell lines, on the other hand, the contribution of the nine expressed EBV latency-associated proteins to B lymphocyte immortalization is well-delineated, making the observed alteration in lymphoblastoid cell growth phenotype accompanying EBV loss almost intuitive. Treatment of a diverse group of eight lymphoid cell lines indicated that the loss of viral episomes (most dramatic in Akata cells) reflects activity of hydroxyurea against the viral episome, not a selective antiproliferative effect against EBVpositive cells in a mixed cell population such as Akata [18] . For example, complete viral DNA loss (figure 5) in subsets of immortalized primary B lymphocytes totally dependent on EBV for growth in culture is convincing evidence for a direct antiviral effect. Two uniformly infected BL lines, Raji and Mutu, had either an overall reduction in EBV DNA content after drug exposure or, at a single-cell level, yielded EBVnegative cell clones. Finally, studies with Akata used freshly derived EBV-positive cell clones that provided a homogeneous cell population. Even if natural loss of episomes occurred in a subset of these cells, Akata cell clones with and without EBV exhibited identical growth kinetics when maintained in 50 mM hydroxyurea. Moreover, viral activation as a consequence of drug exposure was not demonstrated by immunostaining for the viral immediate-early protein BZLF1, ruling out a preferential cytolytic effect in virus-bearing cells.
An antiviral effect from hydroxyurea at nontoxic doses of drug has previously been reported with regard to human immunodeficiency virus type 1 infection both in vitro [47, 48] and in vivo [49] and is based on the drug's ability to decrease the intracellular pool of dNTPs [50] . Hydroxyurea inhibits the cellular ribonucleotide reductase, a rate-limiting enzyme in synthesis of dNTPs required for DNA replication [34] . Propagation of episomal EBV DNA in concert with the cell cycle requires that the viral genome compete effectively for compo- Primary B lymphocyte lines immortalized by EBV were cultured in presence or absence of hydroxyurea. A, IB4, which has viral genome integrated and was derived by infection of umbilical cord blood lymphocytes with laboratory EBV strain B95-8; B, TW236, cord blood lymphocyte line containing throat-washing isolate of EBV in episomal configuration; C, RR, spontaneous peripheral blood lymphocyte transformant containing episomal viral DNA, which was derived from bone marrow transplant recipient with lymphoproliferative disease. tide reductase [57] , known to be resistant to inhibition by hydroxyurea [58] .
The effect of hydroxyurea on maintenance of EBV episomes in tissue culture suggests two immediate applications. As an investigative tool, the drug may facilitate analysis of viral integration, a recurrent theme in tumor virus research but an issue on which little is known regarding EBV-associated tumors. Because of the technical difficulty of detecting a single integration event against a background of multicopy episomes, only a limited number of cell lines with unusually low EBV copy number have been studied and shown to have integrated EBV [59] . Clinically, the activity of hydroxyurea that we report, coupled with the drug's well-known clinical safety profile derived from years of use in human therapy, its ability to diffuse into all tissues, including the central nervous system, and the acceptable toxicities at the low concentrations used here [34, 35] , make it an attractive candidate for immediate clinical trials. phenotype.
